Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

2020177 citationsJournal Articlegold Open Access

Authors

NCT03394287.

Good health and well-being

Published in: Journal for ImmunoTherapy of Cancer

Volume 8, Issue 1, pp. e000696-e000696

Field-Weighted Citation Impact: 8.29